PortalPublikationenMUC1 (CA27.29) before and after Chemotherapy and Prognosis i...

MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

Standard

MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. / Huebner, Hanna; Häberle, Lothar; Müller, Volkmar; Schrader, Iris; Lorenz, Ralf; Forstbauer, Helmut; Fink, Visnja; Schochter, Fabienne; Bekes, Inga; Mahner, Sven; Jückstock, Julia; Nabieva, Naiba; Schneeweiss, Andreas; Tesch, Hans; Brucker, Sara Y; Blohmer, Jens-Uwe; Fehm, Tanja N; Heinrich, Georg; Rezai, Mahdi; Beckmann, Matthias W; Fasching, Peter A; Janni, Wolfgang; Rack, Brigitte.

in: CANCERS, Jahrgang 14, Nr. 7, 1721, 28.03.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Huebner, H, Häberle, L, Müller, V, Schrader, I, Lorenz, R, Forstbauer, H, Fink, V, Schochter, F, Bekes, I, Mahner, S, Jückstock, J, Nabieva, N, Schneeweiss, A, Tesch, H, Brucker, SY, Blohmer, J-U, Fehm, TN, Heinrich, G, Rezai, M, Beckmann, MW, Fasching, PA, Janni, W & Rack, B 2022, 'MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients', CANCERS, Jg. 14, Nr. 7, 1721. https://doi.org/10.3390/cancers14071721

APA

Huebner, H., Häberle, L., Müller, V., Schrader, I., Lorenz, R., Forstbauer, H., Fink, V., Schochter, F., Bekes, I., Mahner, S., Jückstock, J., Nabieva, N., Schneeweiss, A., Tesch, H., Brucker, S. Y., Blohmer, J-U., Fehm, T. N., Heinrich, G., Rezai, M., ... Rack, B. (2022). MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. CANCERS, 14(7), [1721]. https://doi.org/10.3390/cancers14071721

Vancouver

Huebner H, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H et al. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. CANCERS. 2022 Mär 28;14(7). 1721. https://doi.org/10.3390/cancers14071721

Bibtex

@article{d99ff66333f5418588bf3fc728e18bfc,
title = "MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients",
abstract = "Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the SUCCESS-A trial (NCT02181101), assessed the prognostic value of soluble MUC1 before and after standard adjuvant chemotherapy. Patients with high-risk BC were treated within the SUCCESS-A trial with either three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel or three cycles of FEC followed by three cycles of docetaxel and gemcitabine. Cox regression analyses were performed to investigate the prognostic value of CA27.29 before and after chemotherapy relative to disease-free survival (DFS), along with established BC prognostic factors such as age, body mass index, tumor size, nodal status, estrogen receptor, progesterone receptor, HER2 status, and grading. Pre-chemotherapy and post-chemotherapy CA27.29 assessments were available for 2687 patients of 3754 randomized patients. Pre-chemotherapy CA27.29 assessment was associated with DFS in addition to established prognostic factors. It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.",
author = "Hanna Huebner and Lothar H{\"a}berle and Volkmar M{\"u}ller and Iris Schrader and Ralf Lorenz and Helmut Forstbauer and Visnja Fink and Fabienne Schochter and Inga Bekes and Sven Mahner and Julia J{\"u}ckstock and Naiba Nabieva and Andreas Schneeweiss and Hans Tesch and Brucker, {Sara Y} and Jens-Uwe Blohmer and Fehm, {Tanja N} and Georg Heinrich and Mahdi Rezai and Beckmann, {Matthias W} and Fasching, {Peter A} and Wolfgang Janni and Brigitte Rack",
year = "2022",
month = mar,
day = "28",
doi = "10.3390/cancers14071721",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

RIS

TY - JOUR

T1 - MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients

AU - Huebner, Hanna

AU - Häberle, Lothar

AU - Müller, Volkmar

AU - Schrader, Iris

AU - Lorenz, Ralf

AU - Forstbauer, Helmut

AU - Fink, Visnja

AU - Schochter, Fabienne

AU - Bekes, Inga

AU - Mahner, Sven

AU - Jückstock, Julia

AU - Nabieva, Naiba

AU - Schneeweiss, Andreas

AU - Tesch, Hans

AU - Brucker, Sara Y

AU - Blohmer, Jens-Uwe

AU - Fehm, Tanja N

AU - Heinrich, Georg

AU - Rezai, Mahdi

AU - Beckmann, Matthias W

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Rack, Brigitte

PY - 2022/3/28

Y1 - 2022/3/28

N2 - Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the SUCCESS-A trial (NCT02181101), assessed the prognostic value of soluble MUC1 before and after standard adjuvant chemotherapy. Patients with high-risk BC were treated within the SUCCESS-A trial with either three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel or three cycles of FEC followed by three cycles of docetaxel and gemcitabine. Cox regression analyses were performed to investigate the prognostic value of CA27.29 before and after chemotherapy relative to disease-free survival (DFS), along with established BC prognostic factors such as age, body mass index, tumor size, nodal status, estrogen receptor, progesterone receptor, HER2 status, and grading. Pre-chemotherapy and post-chemotherapy CA27.29 assessments were available for 2687 patients of 3754 randomized patients. Pre-chemotherapy CA27.29 assessment was associated with DFS in addition to established prognostic factors. It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.

AB - Soluble MUC1 has been discussed as a biomarker for predicting prognosis, treatment efficacy, and monitoring disease activity in breast cancer (BC) patients. Most studies in adjuvant settings have used preoperative assessment. This study, part of the SUCCESS-A trial (NCT02181101), assessed the prognostic value of soluble MUC1 before and after standard adjuvant chemotherapy. Patients with high-risk BC were treated within the SUCCESS-A trial with either three cycles of 5-fluorouracil, epirubicin, and cyclophosphamide followed by three cycles of docetaxel or three cycles of FEC followed by three cycles of docetaxel and gemcitabine. Cox regression analyses were performed to investigate the prognostic value of CA27.29 before and after chemotherapy relative to disease-free survival (DFS), along with established BC prognostic factors such as age, body mass index, tumor size, nodal status, estrogen receptor, progesterone receptor, HER2 status, and grading. Pre-chemotherapy and post-chemotherapy CA27.29 assessments were available for 2687 patients of 3754 randomized patients. Pre-chemotherapy CA27.29 assessment was associated with DFS in addition to established prognostic factors. It had no prognostic value in node-negative patients, but there was a clear association in node-positive patients. Post-chemotherapy CA27.29 assessment did not add any prognostic value, either on its own or in addition to pre-chemotherapy CA27.29 assessment.

U2 - 10.3390/cancers14071721

DO - 10.3390/cancers14071721

M3 - SCORING: Journal article

C2 - 35406491

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 7

M1 - 1721

ER -